Effects of the Self-Guided Web-Based Intervention vimida on Post–COVID-19 Fatigue: Randomized Controlled Trial (Preprint)
BACKGROUND Persistent fatigue is one of the most debilitating symptoms of post-COVID-19 condition (PCC), also referred to as Long COVID. However, evidence-based and scalable psychological interventions for managing this condition remain scarce. OBJECTIVE This study aimed to evaluate the efficacy of vimida, a self-guided, web-based intervention incorporating techniques from cognitive behavioral therapy, as an adjunct to treatment as usual (TAU) compared to TAU alone in alleviating fatigue among adults with PCC. METHODS We conducted a decentralized, pragmatic randomized controlled trial (RCT) in Germany. Adults (≥18 years) with confirmed PCC (ICD-10: U09.9), chronic fatigue syndrome (ICD-10: G93.3), and a Chalder Fatigue Scale (CFQ-11) score ≥16 were recruited online and randomized (1:1) to either vimida plus TAU (n=88) or TAU alone (n=88). The primary outcome was fatigue severity, measured by the CFQ-11 total score. Secondary outcomes included depressive symptoms (Patient Health Questionnaire-9; PHQ-9), somatic symptoms (Patient Health Questionnaire-15; PHQ-15), health-related quality of life (Assessment of Quality of Life-8D; AQoL-8D), psychosocial functioning (Work and Social Adjustment Scale; WSAS), and anxiety symptoms (Generalized Anxiety Disorder-7; GAD-7). All outcomes were assessed at 3 months, the primary time point of assessment, and at 6 months. Intention-to-treat (ITT) analyses used multiple imputation and baseline-adjusted analysis of covariance. RESULTS In the ITT analysis, vimida plus TAU significantly reduced CFQ-11 scores relative to TAU alone at 3 months (baseline-adjusted mean difference -2.04 points, 95% CI -4.07 to -0.01; P=.049; d=0.30) and 6 months (-2.6 points, 95% CI -4.6 to -0.6; P=.011; d=0.40). Following false discovery rate correction, somatic symptoms at 6 months represented the only statistically significant secondary outcome (PHQ-15: -1.8 points, 95% CI -2.8 to -0.7; P<.001; d=0.54). A prespecified response of a ≥5-point reduction on the CFQ-11 was achieved by 46.6% (41/88) of the intervention group versus 30.7% (27/88) of the control group (χ²₁=4.7; P=.03; odds ratio 1.97, 95% CI 1.06-3.65). All 88 participants in the intervention group registered and engaged with the platform on a mean of 32.4 days (SD 30.0). No adverse events were attributed to vimida. CONCLUSIONS vimida combined with TAU demonstrated small yet clinically meaningful reductions in PCC-related fatigue at 3 and 6 months, with an additional benefit for somatic symptoms at 6 months. As a fully remote intervention, vimida represents a scalable adjunctive treatment option for adults with PCC-related fatigue. CLINICALTRIAL ClinicalTrials.gov NCT06251518; InvidiCO; https://clinicaltrials.gov/study/NCT06251518
Authors
- Britta Menne
- Gitta Anne Jacob (ORCID: https://orcid.org/0000-0003-2380-0118)
- Christian Firus
- Katharina Miriam Rischer (ORCID: https://orcid.org/0000-0003-3509-9760)
- Johanna Schröder (ORCID: https://orcid.org/0000-0002-0751-4720)
Publication Details
- Published
- 2026-11-18
- DOI
- https://doi.org/10.2196/preprints.117198
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- preprint